{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:59:55Z","timestamp":1793973595810,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1245\/s10434-024-16453-9","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T19:57:28Z","timestamp":1731182248000},"page":"1093-1104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of Sustained Virological Response on Long-Term Outcomes After Curative Resection in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma in the Era of Direct-Acting Antiviral Therapy"],"prefix":"10.1245","volume":"32","author":[{"given":"Hayato","family":"Abe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyasu","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Mitsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Aramaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Moriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumie","family":"Ohni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"key":"16453_CR1","doi-asserted-by":"publisher","first-page":"e430028","DOI":"10.1200\/EDBK_430028","volume":"44","author":"P Ntellas","year":"2024","unstructured":"Ntellas P, Chau I. Updates on systemic therapy for hepatocellular carcinoma. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2024;44:e430028. https:\/\/doi.org\/10.1200\/EDBK_430028.","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet."},{"key":"16453_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/hepr.13503","volume":"50","author":"Drafting Committee for Hepatitis Management Guidelines tJSoH","year":"2020","unstructured":"Drafting Committee for Hepatitis Management Guidelines tJSoH. Japan society of hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020;50:791\u2013816.","journal-title":"Hepatol Res."},{"key":"16453_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hepr.13892","volume":"53","author":"K Hasegawa","year":"2023","unstructured":"Hasegawa K, Takemura N, Yamashita T, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2021 version (5th JSH-HCC guidelines). Hepatol Res. 2023;53:383\u201390.","journal-title":"Hepatol Res."},{"key":"16453_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11605-016-3344-3","volume":"21","author":"K Sasaki","year":"2017","unstructured":"Sasaki K, Shindoh J, Nishioka Y, et al. Impact of viral etiology on postoperative de novo recurrence after hepatectomy for hepatocellular carcinoma in cirrhotic patients. J Gastrointest Surg. 2017;21:487\u201395.","journal-title":"J Gastrointest Surg."},{"key":"16453_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174\u201381.","journal-title":"Ann Intern Med."},{"key":"16453_CR6","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad F, Hezode C, Trinh R, et al. ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973\u201382.","journal-title":"N Engl J Med."},{"key":"16453_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","volume":"71","author":"G Cabibbo","year":"2019","unstructured":"Cabibbo G, Celsa C, Calvaruso V, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019;71:265\u201373.","journal-title":"J Hepatol."},{"key":"16453_CR8","doi-asserted-by":"publisher","first-page":"e0194704","DOI":"10.1371\/journal.pone.0194704","volume":"13","author":"T Mashiba","year":"2018","unstructured":"Mashiba T, Joko K, Kurosaki M, et al. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the japanese red cross hospital liver study group. PloS One. 2018;13:e0194704.","journal-title":"PloS One."},{"key":"16453_CR9","unstructured":"The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer, 6th ed. revised version. Tokyo, Japan: Kanehara & Co, Ltd; 2015"},{"key":"16453_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/archsurg.136.8.922","volume":"136","author":"T Takayama","year":"2001","unstructured":"Takayama T, Makuuchi M, Kubota K, et al. Randomized comparison of ultrasonic vs clamp transection of the liver. Arch Surg. 2001;136:922\u20138.","journal-title":"Arch Surg."},{"key":"16453_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg."},{"key":"16453_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.surg.2022.11.001","volume":"173","author":"H Abe","year":"2023","unstructured":"Abe H, Shibutani K, Yamazaki S, et al. Tumor stiffness measurement using magnetic resonance elastography can predict recurrence and survival after curative resection of hepatocellular carcinoma. Surgery. 2023;173:450\u20136.","journal-title":"Surgery."},{"key":"16453_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology. 1996;24:289\u201393.","journal-title":"Hepatology."},{"key":"16453_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00535-020-01747-y","volume":"56","author":"H Ochi","year":"2021","unstructured":"Ochi H, Hiraoka A, Hirooka M, et al. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol. 2021;56:90\u2013100.","journal-title":"J Gastroenterol."},{"key":"16453_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150\u201361.","journal-title":"Pharm Stat."},{"key":"16453_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jvh.13627","volume":"29","author":"H Ikenaga","year":"2022","unstructured":"Ikenaga H, Uchida-Kobayashi S, Tamori A, et al. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat. 2022;29:52\u20139.","journal-title":"J Viral Hepat."},{"key":"16453_CR17","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1245\/s10434-019-07911-w","volume":"26","author":"Y Okamura","year":"2019","unstructured":"Okamura Y, Sugiura T, Ito T, et al. The achievement of a sustained virological response either before or after hepatectomy improves the prognosis of patients with primary hepatitis C virus-related hepatocellular carcinoma. Ann Surg Oncol. 2019;26:4566\u201375.","journal-title":"Ann Surg Oncol."},{"key":"16453_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/medicina58020259","volume":"58","author":"YS Chen","year":"2022","unstructured":"Chen YS, Huang KH, Wang PM, et al. The impact of direct-acting antiviral therapy on the risk of recurrence after curative resection in patients with hepatitis-C-virus-related early stage hepatocellular carcinoma. Medicina. 2022;58:259. https:\/\/doi.org\/10.3390\/medicina58020259.","journal-title":"Medicina."},{"key":"16453_CR19","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. Electronic address EEE, clinical practice guidelines panel C, representative EGB, et al. EASL recommendations on treatment of hepatitis C: final update of the series(\u2606). J Hepatol. 2020;73:1170\u2013218.","journal-title":"J Hepatol."},{"key":"16453_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"M Reig","year":"2016","unstructured":"Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719\u201326.","journal-title":"J Hepatol."},{"key":"16453_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jmv.25352","volume":"91","author":"Y Nagaoki","year":"2019","unstructured":"Nagaoki Y, Imamura M, Nishida Y, et al. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: comparison with interferon-based therapy. J Med Virol. 2019;91:650\u20138.","journal-title":"J Med Virol."},{"key":"16453_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/hep.32341","volume":"76","author":"I Lockart","year":"2022","unstructured":"Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis. Hepatology. 2022;76:139\u2013154.","journal-title":"Hepatology"},{"key":"16453_CR23","doi-asserted-by":"publisher","first-page":"e2021173","DOI":"10.1001\/jamanetworkopen.2020.21173","volume":"3","author":"Q Chen","year":"2020","unstructured":"Chen Q, Ayer T, Adee MG, Wang X, Kanwal F, Chhatwal J. Assessment of incidence of and surveillance burden for hepatocellular carcinoma among patients with hepatitis C in the era of direct-acting antiviral agents. JAMA Netw Open. 2020;3:e2021173. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.21173.","journal-title":"JAMA Netw Open."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16453-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16453-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16453-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T17:04:49Z","timestamp":1735923889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16453-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["16453"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16453-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}